New study explores surgery hope for inoperable pancreatic cancer
NCT ID NCT07241663
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at patients with locally advanced pancreatic cancer that cannot be removed by surgery at first. After at least 4 months of chemotherapy, if the tumor shrinks enough, doctors may consider surgery. The goal is to see if this approach helps patients live longer and maintain a better quality of life. About 150 adults from expert centers around the world will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2025
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patient with hystologically proved locally advanced pancreatic adenocarcinoma
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients older than 18 years * Patients able to give informed consent * Histologically confirmed pancreatic adenocarcinoma * LAPC stage according to NCCN10 at diagnosis (Figure 1) * Received at least 4 months of induction chemotherapy * RECIST 1.1 stable disease (SD) or partial response (PR) after induction therapy * Patient considered eligible for radical resection by local MDT Exclusion Criteria: * Informed consent withdrawal * Presence of tumor characteristics precluding surgery * Presence of patient significant comorbidities precluding surgery * Unavailable pre-induction therapy abdominal imaging * Pathological confirmation of any tumor different from PDAC
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Locally advanced pancreatic adenocarcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
UOC Chirurgia Generale 2, Azienda Ospedale di Padova, Padova, Italy 35128
RECRUITINGPadova, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Four-Drug cocktail aims to shrink pancreatic tumors before surgery
- Immune cells armed with antibody take on pancreatic cancer
- New drug AB801 aims to boost chemo and immunotherapy in tough cancers
- New PET tracer could light up pancreatic tumors
- New drug combo aims to tackle pancreatic cancer in patients with inherited gene mutations
- Blasting pancreatic tumors with extra radiation may open door to surgery